Research Analysts Issue Forecasts for COCP Q1 Earnings

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Zacks Research issued their Q1 2026 earnings estimates for Cocrystal Pharma in a research note issued on Tuesday, April 7th. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of ($0.16) for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.85) per share. Zacks Research also issued estimates for Cocrystal Pharma’s Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.73) EPS and FY2027 earnings at ($0.64) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Cocrystal Pharma Price Performance

COCP opened at $1.43 on Thursday. Cocrystal Pharma has a 1-year low of $0.86 and a 1-year high of $2.67. The stock has a market cap of $19.72 million, a P/E ratio of -1.81 and a beta of 1.18. The stock’s 50 day simple moving average is $1.07 and its 200 day simple moving average is $1.07.

Cocrystal Pharma (NASDAQ:COCP) last issued its earnings results on Tuesday, March 31st. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01.

Insiders Place Their Bets

In other news, Director Phillip Md Et Al Frost bought 50,000 shares of the stock in a transaction on Friday, February 6th. The shares were bought at an average price of $0.95 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director owned 1,888,551 shares of the company’s stock, valued at approximately $1,794,123.45. This trade represents a 2.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 28.14% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.72% of the company’s stock.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.